182 related articles for article (PubMed ID: 11505218)
1. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
Ramamoorthy Y; Tyndale RF; Sellers EM
Pharmacogenetics; 2001 Aug; 11(6):477-87. PubMed ID: 11505218
[TBL] [Abstract][Full Text] [Related]
2. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
Ramamoorthy Y; Yu AM; Suh N; Haining RL; Tyndale RF; Sellers EM
Biochem Pharmacol; 2002 Jun; 63(12):2111-9. PubMed ID: 12110370
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory and Stimulatory Effects of Selective Serotonin Reuptake Inhibitors on Cytochrome P450 2D6-mediated Dopamine Formation from p-Tyramine.
Niwa T; Sugimoto S
J Pharm Pharm Sci; 2019; 22(1):585-592. PubMed ID: 31804922
[TBL] [Abstract][Full Text] [Related]
6. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
[TBL] [Abstract][Full Text] [Related]
8. Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on the N-demethylation of amitriptyline in vitro.
Weng Q; Liang B; Zhou Y; Li X; Wang H; Zhan Y; Dai D; Cai J; Hu G
Pharm Biol; 2016 Nov; 54(11):2475-2479. PubMed ID: 27097346
[TBL] [Abstract][Full Text] [Related]
9. Interactions of amphetamine analogs with human liver CYP2D6.
Wu D; Otton SV; Inaba T; Kalow W; Sellers EM
Biochem Pharmacol; 1997 Jun; 53(11):1605-12. PubMed ID: 9264312
[TBL] [Abstract][Full Text] [Related]
10. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
Ewald AH; Maurer HH
Toxicol Lett; 2008 Dec; 183(1-3):52-7. PubMed ID: 18938231
[TBL] [Abstract][Full Text] [Related]
11. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator.
Jornil J; Jensen KG; Larsen F; Linnet K
Drug Metab Dispos; 2010 Mar; 38(3):376-85. PubMed ID: 20007670
[TBL] [Abstract][Full Text] [Related]
12. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
[TBL] [Abstract][Full Text] [Related]
13. Comparison of catalytical activity and stereoselectivity between the recombinant human cytochrome P450 2D6.1 and 2D6.10.
Kong LM; Qian MR; Hu HH; Xu SY; Yu LS; Jiang HD; Chen SQ; Zeng S
Pharmazie; 2012 May; 67(5):440-7. PubMed ID: 22764579
[TBL] [Abstract][Full Text] [Related]
14. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
[TBL] [Abstract][Full Text] [Related]
15. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
[TBL] [Abstract][Full Text] [Related]
16. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
Crewe HK; Lennard MS; Tucker GT; Woods FR; Haddock RE
Br J Clin Pharmacol; 1992 Sep; 34(3):262-5. PubMed ID: 1389951
[TBL] [Abstract][Full Text] [Related]
17. Venlafaxine oxidation in vitro is catalysed by CYP2D6.
Otton SV; Ball SE; Cheung SW; Inaba T; Rudolph RL; Sellers EM
Br J Clin Pharmacol; 1996 Feb; 41(2):149-56. PubMed ID: 8838442
[TBL] [Abstract][Full Text] [Related]
18. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
Desmarais JE; Looper KJ
J Clin Psychiatry; 2009 Dec; 70(12):1688-97. PubMed ID: 20141708
[TBL] [Abstract][Full Text] [Related]
19. Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation.
Rodgers JT; Davydova NY; Paragas EM; Jones JP; Davydov DR
Biochem Pharmacol; 2018 Oct; 156():86-98. PubMed ID: 30114388
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
